Cargando…
Comparative Study of Short-Term Efficacy and Safety of Mitomycin versus Lobaplatin for Hyperthermic Intraperitoneal Chemotherapy after Radical Surgery in Colorectal Cancer with High-Risk Factors for Peritoneal Carcinomatosis: A Propensity Score Matching Analysis
Background: The drug selection of radical surgery (RS), with hyperthermic intraperitoneal chemotherapy (HIPEC), in pT4 colorectal cancer (CRC) remains controversial. Methods: Adverse events after HIPEC were estimated by common terminology criteria for adverse events version 5.0. The efficacy was eva...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955354/ https://www.ncbi.nlm.nih.gov/pubmed/36826075 http://dx.doi.org/10.3390/curroncol30020114 |
_version_ | 1784894327077470208 |
---|---|
author | Guo, Xikai Lin, Yao Shen, Chu Li, Yuan Xiang, Fan Ruan, Tuo Zeng, Xinyu Lv, Jianbo Tao, Kaixiong Wu, Chuanqing |
author_facet | Guo, Xikai Lin, Yao Shen, Chu Li, Yuan Xiang, Fan Ruan, Tuo Zeng, Xinyu Lv, Jianbo Tao, Kaixiong Wu, Chuanqing |
author_sort | Guo, Xikai |
collection | PubMed |
description | Background: The drug selection of radical surgery (RS), with hyperthermic intraperitoneal chemotherapy (HIPEC), in pT4 colorectal cancer (CRC) remains controversial. Methods: Adverse events after HIPEC were estimated by common terminology criteria for adverse events version 5.0. The efficacy was evaluated using overall survival (OS) and recurrence-free rate (RFR). Propensity score matching (PSM) was used to reduce the influence of confounders between Mitomycin and Lobaplatin groups. Results: Of the 146 patients, from April 2020 to March 2021, 47 were managed with mitomycin and 99 with lobaplatin. There was no significant difference in the incidence of all adverse events between the two groups after PSM. OS and RFR were not significantly different between the two groups at 22 months (p = 0.410; p = 0.310). OS and RFR of the two groups also showed no significant difference for patients with T4a or T4b stage, tumor size < or ≥ 5 cm. Among patients with colon cancer, RFR at 22 months of the two groups was significantly different (100.0% vs. 63.2%, p = 0.028). Conclusions: In summary, the safety of mitomycin and lobaplatin for HIPEC was not different. Compared with lobaplatin, mitomycin for HIPEC after RS could benefit patients with colon cancer in RFR. |
format | Online Article Text |
id | pubmed-9955354 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99553542023-02-25 Comparative Study of Short-Term Efficacy and Safety of Mitomycin versus Lobaplatin for Hyperthermic Intraperitoneal Chemotherapy after Radical Surgery in Colorectal Cancer with High-Risk Factors for Peritoneal Carcinomatosis: A Propensity Score Matching Analysis Guo, Xikai Lin, Yao Shen, Chu Li, Yuan Xiang, Fan Ruan, Tuo Zeng, Xinyu Lv, Jianbo Tao, Kaixiong Wu, Chuanqing Curr Oncol Article Background: The drug selection of radical surgery (RS), with hyperthermic intraperitoneal chemotherapy (HIPEC), in pT4 colorectal cancer (CRC) remains controversial. Methods: Adverse events after HIPEC were estimated by common terminology criteria for adverse events version 5.0. The efficacy was evaluated using overall survival (OS) and recurrence-free rate (RFR). Propensity score matching (PSM) was used to reduce the influence of confounders between Mitomycin and Lobaplatin groups. Results: Of the 146 patients, from April 2020 to March 2021, 47 were managed with mitomycin and 99 with lobaplatin. There was no significant difference in the incidence of all adverse events between the two groups after PSM. OS and RFR were not significantly different between the two groups at 22 months (p = 0.410; p = 0.310). OS and RFR of the two groups also showed no significant difference for patients with T4a or T4b stage, tumor size < or ≥ 5 cm. Among patients with colon cancer, RFR at 22 months of the two groups was significantly different (100.0% vs. 63.2%, p = 0.028). Conclusions: In summary, the safety of mitomycin and lobaplatin for HIPEC was not different. Compared with lobaplatin, mitomycin for HIPEC after RS could benefit patients with colon cancer in RFR. MDPI 2023-01-21 /pmc/articles/PMC9955354/ /pubmed/36826075 http://dx.doi.org/10.3390/curroncol30020114 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Guo, Xikai Lin, Yao Shen, Chu Li, Yuan Xiang, Fan Ruan, Tuo Zeng, Xinyu Lv, Jianbo Tao, Kaixiong Wu, Chuanqing Comparative Study of Short-Term Efficacy and Safety of Mitomycin versus Lobaplatin for Hyperthermic Intraperitoneal Chemotherapy after Radical Surgery in Colorectal Cancer with High-Risk Factors for Peritoneal Carcinomatosis: A Propensity Score Matching Analysis |
title | Comparative Study of Short-Term Efficacy and Safety of Mitomycin versus Lobaplatin for Hyperthermic Intraperitoneal Chemotherapy after Radical Surgery in Colorectal Cancer with High-Risk Factors for Peritoneal Carcinomatosis: A Propensity Score Matching Analysis |
title_full | Comparative Study of Short-Term Efficacy and Safety of Mitomycin versus Lobaplatin for Hyperthermic Intraperitoneal Chemotherapy after Radical Surgery in Colorectal Cancer with High-Risk Factors for Peritoneal Carcinomatosis: A Propensity Score Matching Analysis |
title_fullStr | Comparative Study of Short-Term Efficacy and Safety of Mitomycin versus Lobaplatin for Hyperthermic Intraperitoneal Chemotherapy after Radical Surgery in Colorectal Cancer with High-Risk Factors for Peritoneal Carcinomatosis: A Propensity Score Matching Analysis |
title_full_unstemmed | Comparative Study of Short-Term Efficacy and Safety of Mitomycin versus Lobaplatin for Hyperthermic Intraperitoneal Chemotherapy after Radical Surgery in Colorectal Cancer with High-Risk Factors for Peritoneal Carcinomatosis: A Propensity Score Matching Analysis |
title_short | Comparative Study of Short-Term Efficacy and Safety of Mitomycin versus Lobaplatin for Hyperthermic Intraperitoneal Chemotherapy after Radical Surgery in Colorectal Cancer with High-Risk Factors for Peritoneal Carcinomatosis: A Propensity Score Matching Analysis |
title_sort | comparative study of short-term efficacy and safety of mitomycin versus lobaplatin for hyperthermic intraperitoneal chemotherapy after radical surgery in colorectal cancer with high-risk factors for peritoneal carcinomatosis: a propensity score matching analysis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955354/ https://www.ncbi.nlm.nih.gov/pubmed/36826075 http://dx.doi.org/10.3390/curroncol30020114 |
work_keys_str_mv | AT guoxikai comparativestudyofshorttermefficacyandsafetyofmitomycinversuslobaplatinforhyperthermicintraperitonealchemotherapyafterradicalsurgeryincolorectalcancerwithhighriskfactorsforperitonealcarcinomatosisapropensityscorematchinganalysis AT linyao comparativestudyofshorttermefficacyandsafetyofmitomycinversuslobaplatinforhyperthermicintraperitonealchemotherapyafterradicalsurgeryincolorectalcancerwithhighriskfactorsforperitonealcarcinomatosisapropensityscorematchinganalysis AT shenchu comparativestudyofshorttermefficacyandsafetyofmitomycinversuslobaplatinforhyperthermicintraperitonealchemotherapyafterradicalsurgeryincolorectalcancerwithhighriskfactorsforperitonealcarcinomatosisapropensityscorematchinganalysis AT liyuan comparativestudyofshorttermefficacyandsafetyofmitomycinversuslobaplatinforhyperthermicintraperitonealchemotherapyafterradicalsurgeryincolorectalcancerwithhighriskfactorsforperitonealcarcinomatosisapropensityscorematchinganalysis AT xiangfan comparativestudyofshorttermefficacyandsafetyofmitomycinversuslobaplatinforhyperthermicintraperitonealchemotherapyafterradicalsurgeryincolorectalcancerwithhighriskfactorsforperitonealcarcinomatosisapropensityscorematchinganalysis AT ruantuo comparativestudyofshorttermefficacyandsafetyofmitomycinversuslobaplatinforhyperthermicintraperitonealchemotherapyafterradicalsurgeryincolorectalcancerwithhighriskfactorsforperitonealcarcinomatosisapropensityscorematchinganalysis AT zengxinyu comparativestudyofshorttermefficacyandsafetyofmitomycinversuslobaplatinforhyperthermicintraperitonealchemotherapyafterradicalsurgeryincolorectalcancerwithhighriskfactorsforperitonealcarcinomatosisapropensityscorematchinganalysis AT lvjianbo comparativestudyofshorttermefficacyandsafetyofmitomycinversuslobaplatinforhyperthermicintraperitonealchemotherapyafterradicalsurgeryincolorectalcancerwithhighriskfactorsforperitonealcarcinomatosisapropensityscorematchinganalysis AT taokaixiong comparativestudyofshorttermefficacyandsafetyofmitomycinversuslobaplatinforhyperthermicintraperitonealchemotherapyafterradicalsurgeryincolorectalcancerwithhighriskfactorsforperitonealcarcinomatosisapropensityscorematchinganalysis AT wuchuanqing comparativestudyofshorttermefficacyandsafetyofmitomycinversuslobaplatinforhyperthermicintraperitonealchemotherapyafterradicalsurgeryincolorectalcancerwithhighriskfactorsforperitonealcarcinomatosisapropensityscorematchinganalysis |